Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The company is headquartered in Boston, Massachusetts and currently employs 283 full-time employees. The company went IPO on 2017-10-05. The firm is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE, as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. IMCIVREE is approved by the Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients six years of age and older with monogenic or syndromic obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS). In addition to setmelanotide, it has two earlier-stage investigational MC4R agonists in clinical development, RM-718, designed for weekly administration, and bivamelagon, an oral small molecule.
Follow-Up Questions
Who is the CEO of Rhythm Pharmaceuticals Inc?
Dr. David Meeker is the Chairman of the Board of Rhythm Pharmaceuticals Inc, joining the firm since 2015.
What is the price performance of RYTM stock?
The current price of RYTM is $109.35, it has decreased 0.83% in the last trading day.
What are the primary business themes or industries for Rhythm Pharmaceuticals Inc?
Rhythm Pharmaceuticals Inc belongs to Biotechnology industry and the sector is Health Care
What is Rhythm Pharmaceuticals Inc market cap?
Rhythm Pharmaceuticals Inc's current market cap is $7.2B
Is Rhythm Pharmaceuticals Inc a buy, sell, or hold?
According to wall street analysts, 16 analysts have made analyst ratings for Rhythm Pharmaceuticals Inc, including 8 strong buy, 11 buy, 1 hold, 0 sell, and 8 strong sell
